Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study Of Pf-03084014 In Combination With Gemcitabine And Nab-paclitaxel In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Next Previous
Trial Profile

Phase 1/2 Study Of Pf-03084014 In Combination With Gemcitabine And Nab-paclitaxel In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nirogacestat (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 16 Jul 2015 Planned End Date changed from 1 Apr 2019 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
  • 16 Jul 2015 Planned primary completion date changed from 1 Apr 2019 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
  • 16 Jul 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top